controlled trial · 2023
“The improvements in several cardiovascular risk factors—total and LDL cholesterol, diastolic blood pressure, and body weight—observed in this physiologic study need confirmation in larger trials of longer duration.”
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab
Who: Community-dwelling overweight or obese (BMI 25-42.5) men and postmenopausal women aged 45 years or older without diabetes or significant medical problems; mean age 61.9
PMID 36740954
controlled trial · 2023
“However, no significant difference was observed in the average baPWV values between the two groups ( p = 0.097).”
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep
Who: Apparently healthy Japanese men and women aged 40-59 years (no diabetes or serious comorbidity), mean age about 48
PMID 36797393
other primary study · 2023 · landmark
“The open study setting and the lack of a statistically powered placebo group may compromise our results related to body composition and metabolic health, and these endpoints need to be followed up in larger placebo-controlled trials.”
Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci Adv
Who: Finnish monozygotic twins aged ~40 (IQR 33 to 41), mostly overweight or obese (mean BMI ~30-32) and largely metabolically healthy: 16 BMI-discordant pairs (all on NR) and 4 BMI-concordant pairs (one cotwin NR, one placebo)
PMID 36638183